Evaxion Biotech A/S (NASDAQ:EVAX) Receives “Buy” Rating from HC Wainwright

Evaxion Biotech A/S (NASDAQ:EVAX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They presently have a $14.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 344.44% from the stock’s current price.

Evaxion Biotech A/S Stock Up 1.0 %

EVAX opened at $3.15 on Friday. The company has a market capitalization of $17.04 million, a P/E ratio of -0.73 and a beta of -0.27. The company has a debt-to-equity ratio of 7.99, a current ratio of 2.80 and a quick ratio of 2.80. The firm’s fifty day moving average price is $3.01 and its two-hundred day moving average price is $3.31. Evaxion Biotech A/S has a fifty-two week low of $2.26 and a fifty-two week high of $13.61.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its earnings results on Wednesday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.14). The company had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.10 million. During the same quarter in the prior year, the firm posted ($2.10) earnings per share. On average, analysts anticipate that Evaxion Biotech A/S will post -0.24 EPS for the current year.

Hedge Funds Weigh In On Evaxion Biotech A/S

A number of large investors have recently modified their holdings of EVAX. Invst LLC acquired a new stake in shares of Evaxion Biotech A/S in the second quarter valued at approximately $156,000. Armistice Capital LLC increased its stake in shares of Evaxion Biotech A/S by 6.8% in the 2nd quarter. Armistice Capital LLC now owns 392,000 shares of the company’s stock valued at $1,137,000 after buying an additional 25,000 shares during the period. Finally, LM Advisors LLC acquired a new stake in shares of Evaxion Biotech A/S in the 4th quarter valued at $231,000. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.